Current:Home > InvestCVS Health lays out changes to clarify prescription drug pricing that may save some customers money -Aspire Capital Guides
CVS Health lays out changes to clarify prescription drug pricing that may save some customers money
View
Date:2025-04-24 11:40:14
CVS Health is introducing changes to how its prescription drug pricing model works, and that could lead to some savings for customers starting next year.
The health care giant said Tuesday that it will role out a new reimbursement model designed to make costs more predictable at the drugstore counter. The company will start offering it next year to some third-party cash discount card administrators.
Cash discount cards like those offered by GoodRx can give customers a price break on out-of-pocket costs for some prescriptions, depending on the person’s coverage and the drug.
CVS Health drugstores will start using the company’s new CostVantage model more broadly in 2025. It is designed to make drug costs more transparent. It involves a formula based on the cost of the drug, a set markup and then a fee for filling the prescription.
CVS Health runs one of the nation’s largest drugstore chains and a large pharmacy benefit management business that operates prescription drug coverage for big clients like insurers and employers.
It also sells health insurance through its Aetna arm, and the company has been providing a growing amount of care through its drugstores and clinics.
The company also announced on Tuesday a 10% hike in its quarterly dividend and laid out its forecast for next year. CVS Health expects adjusted earnings of at least $8.50 per share. It also forecasts total revenue of at least $366 billion.
Analysts expect earnings of $8.51 per share on $344.5 billion in revenue, according to FactSet.
Edward Jones analyst John Boylan said in an email that he saw the stronger-than-expected revenue guidance and dividend hike as a “show of confidence by management.”
Shares of CVS Health Corp., based in Woonsocket, Rhode Island, jumped 4%, or $2.76 to $71.25 in early trading while broader indexes slipped.
veryGood! (8)
Related
- New data highlights 'achievement gap' for students in the US
- Yellowstone’s Grizzlies Wandering Farther from Home and Dying in Higher Numbers
- What really happened the night Marianne Shockley died? Evil came to play, says boyfriend acquitted of her murder
- Private opulence, public squalor: How the U.S. helps the rich and hurts the poor
- McKinsey to pay $650 million after advising opioid maker on how to 'turbocharge' sales
- What is Shigella, the increasingly drug-resistant bacteria the CDC is warning about?
- What is Shigella, the increasingly drug-resistant bacteria the CDC is warning about?
- Dakota Pipeline Builder Rebuffed by Feds in Bid to Restart Work on Troubled Ohio Gas Project
- All That You Wanted to Know About She’s All That
- Spills on Aging Enbridge Pipeline Have Topped 1 Million Gallons, Report Says
Ranking
- Grammy nominee Teddy Swims on love, growth and embracing change
- This Week in Clean Economy: New Report Puts Solyndra Media Coverage in Spotlight
- Ja Morant suspended for 25 games without pay, NBA announces
- This safety-net hospital doctor treats mostly uninsured and undocumented patients
- Meet first time Grammy nominee Charley Crockett
- A months-long landfill fire in Alabama reveals waste regulation gaps
- Coasts Should Plan for 6.5 Feet Sea Level Rise by 2100 as Precaution, Experts Say
- You'll Be Crazy in Love With Beyoncé and Jay-Z's London Photo Diary
Recommendation
'Kraven the Hunter' spoilers! Let's dig into that twisty ending, supervillain reveal
This Week in Clean Economy: Major Solar Projects Caught Up in U.S.-China Trade War
Bob Huggins resigns as West Virginia men's basketball coach after DUI arrest in Pittsburgh
Come on Barbie, Let's Go Shopping: Forever 21 Just Launched an Exclusive Barbie Collection
IRS recovers $4.7 billion in back taxes and braces for cuts with Trump and GOP in power
The Smiths Bassist Andy Rourke Dead at 59 After Cancer Battle
This Week in Clean Economy: Can Electric Cars Win Over Consumers in 2012?
How well does a new Alzheimer's drug work for those most at risk?